Notice: This company has been marked as potentially delisted and may not be actively trading. Obalon Therapeutics (OBLN) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrends OBLN vs. INFU, SGHT, ARAY, PROF, SKIN, NVRO, BWAY, KRMD, DRTS, and SRTSShould you be buying Obalon Therapeutics stock or one of its competitors? The main competitors of Obalon Therapeutics include InfuSystem (INFU), Sight Sciences (SGHT), Accuray (ARAY), Profound Medical (PROF), Beauty Health (SKIN), Nevro (NVRO), BrainsWay (BWAY), KORU Medical Systems (KRMD), Alpha Tau Medical (DRTS), and Sensus Healthcare (SRTS). These companies are all part of the "medical" sector. Obalon Therapeutics vs. InfuSystem Sight Sciences Accuray Profound Medical Beauty Health Nevro BrainsWay KORU Medical Systems Alpha Tau Medical Sensus Healthcare Obalon Therapeutics (NASDAQ:OBLN) and InfuSystem (NYSE:INFU) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their community ranking, media sentiment, earnings, analyst recommendations, institutional ownership, dividends, risk, valuation and profitability. Do analysts recommend OBLN or INFU? InfuSystem has a consensus price target of $13.00, indicating a potential upside of 42.70%. Given InfuSystem's stronger consensus rating and higher probable upside, analysts clearly believe InfuSystem is more favorable than Obalon Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Obalon Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00InfuSystem 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 2 Strong Buy rating(s) 4.00 Which has more risk & volatility, OBLN or INFU? Obalon Therapeutics has a beta of -1.23, indicating that its stock price is 223% less volatile than the S&P 500. Comparatively, InfuSystem has a beta of 1.45, indicating that its stock price is 45% more volatile than the S&P 500. Is OBLN or INFU more profitable? InfuSystem has a net margin of 1.12% compared to Obalon Therapeutics' net margin of -776.76%. InfuSystem's return on equity of 2.78% beat Obalon Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Obalon Therapeutics-776.76% -161.38% -83.58% InfuSystem 1.12%2.78%1.41% Does the media prefer OBLN or INFU? In the previous week, InfuSystem had 3 more articles in the media than Obalon Therapeutics. MarketBeat recorded 3 mentions for InfuSystem and 0 mentions for Obalon Therapeutics. Obalon Therapeutics' average media sentiment score of 0.00 equaled InfuSystem'saverage media sentiment score. Company Overall Sentiment Obalon Therapeutics Neutral InfuSystem Neutral Which has stronger valuation & earnings, OBLN or INFU? InfuSystem has higher revenue and earnings than Obalon Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioObalon Therapeutics$1.59M31.77-$12.33MN/AN/AInfuSystem$125.79M1.54$870K$0.06151.86 Do institutionals & insiders hold more shares of OBLN or INFU? 18.6% of Obalon Therapeutics shares are held by institutional investors. Comparatively, 71.1% of InfuSystem shares are held by institutional investors. 8.1% of Obalon Therapeutics shares are held by insiders. Comparatively, 10.2% of InfuSystem shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Does the MarketBeat Community prefer OBLN or INFU? Obalon Therapeutics received 240 more outperform votes than InfuSystem when rated by MarketBeat users. However, 100.00% of users gave InfuSystem an outperform vote while only 48.62% of users gave Obalon Therapeutics an outperform vote. CompanyUnderperformOutperformObalon TherapeuticsOutperform Votes24648.62% Underperform Votes26051.38% InfuSystemOutperform Votes6100.00% Underperform VotesNo Votes SummaryInfuSystem beats Obalon Therapeutics on 14 of the 16 factors compared between the two stocks. Ad Priority GoldJD Vance Predicts: Wall Street vs. Trump & Your MoneyTrump's back in the White House, but Wall Street is pissed. Here's the deal: Wall Street's about to purposely crash the bond market to sabotage Trump's comeback.Get your free guide NOW before it's too late. Get Obalon Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for OBLN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OBLN vs. The Competition Export to ExcelMetricObalon TherapeuticsSurgical & Medical Instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$50.51M$4.47B$5.09B$8.79BDividend YieldN/A36.79%5.04%4.07%P/E Ratio-3.7314.1093.0914.02Price / Sales31.7744.061,220.6787.41Price / CashN/A52.2739.4936.27Price / Book8.405.786.936.33Net Income-$12.33M$13.76M$118.83M$225.71M Obalon Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OBLNObalon TherapeuticsN/A$5.04-1.4%N/A+2,000.0%$50.51M$1.59M-3.732Analyst ForecastINFUInfuSystem1.7054 of 5 stars$9.19+1.9%$13.00+41.5%N/A$195.38M$125.79M153.19499SGHTSight Sciences2.3288 of 5 stars$3.76+0.8%$5.50+46.3%+63.6%$190.86M$81.06M-3.69210ARAYAccuray4.7052 of 5 stars$1.89+2.7%$9.00+377.5%-32.5%$189.57M$446.55M-10.94987Analyst RevisionPROFProfound Medical1.7205 of 5 stars$7.52-2.2%$13.75+82.8%-31.2%$185.44M$7.20M-5.61150SKINBeauty Health2.9718 of 5 stars$1.40-6.1%$2.55+82.8%-36.3%$173.01M$398M-3.321,030Analyst RevisionPositive NewsNVRONevro2.8971 of 5 stars$4.43+4.7%$9.10+105.2%-74.5%$166.16M$425.17M-2.241,215Analyst UpgradeBWAYBrainsWay4.195 of 5 stars$9.84+0.1%$13.17+33.8%+103.9%$164.13M$31.78M98.31120KRMDKORU Medical Systems2.0562 of 5 stars$3.58-1.9%$4.13+15.2%+60.1%$164.11M$28.52M-14.3280DRTSAlpha Tau Medical2.4016 of 5 stars$2.30flat$8.00+248.6%-20.7%$159.89MN/A-5.3480SRTSSensus Healthcare4.0912 of 5 stars$8.95+0.1%$12.50+39.7%+331.9%$146.69M$24.41M15.3940Analyst ForecastAnalyst Revision Related Companies and Tools Related Companies INFU Competitors SGHT Competitors ARAY Competitors PROF Competitors SKIN Competitors NVRO Competitors BWAY Competitors KRMD Competitors DRTS Competitors SRTS Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:OBLN) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Obalon Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Obalon Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free OBLN Stock Alerts